Table 2 Treatment-related characteristics
From: Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma
Treatment-related variables (n = 58) | Treatments, n (%) |
|---|---|
Site | |
Head and neck | 6(10.3%) |
Lung | 17(29.3%) |
Chest | 5(8.6%) |
Abdomen/pelvis | 18(31.0%) |
Vertebral body bone | 10(17.2%) |
Limbs | 2(3.4%) |
Lesions size: median (range) | 5.5 cm (1.6–20 cm) |
<5.0 cm | 26(44.8%) |
≥ 5.0 cm | 32(55.2%) |
BED: median (range) | 85.5 Gy (51.3–187.5 Gy) |
< 100 Gy | 31(53.4%) |
≥ 100 Gy | 27(46.6%) |
Prescription dose (Gy)/fraction | 45 Gy(30–75)/5 Fx(2–10 Fx) |
Median (range) | |
30 Gy/3 Fx | 8 |
45–48 Gy/3–4 Fx | 4 |
54–60 Gy/3 Fx | 3 |
40 Gy/5 Fx | 5 |
45 Gy/5 Fx | 11 |
50 Gy/5 Fx | 15 |
Others | 12 |
Isodose (%): median (range) | 75% (55–88%) |
CI: median (range) | 1.13(1.00–2.77) |
nCI: median (range) | 1.42(1.13–2.93) |
HI: median (range) | 1.33(1.10–2.00) |
PTV coverage: median (range) | 86.12% (47.81–99.75%) |